[HTML][HTML] Lysosomal storage disease overview
A Sun - Annals of translational medicine, 2018 - ncbi.nlm.nih.gov
The lysosomal storage diseases (LSDs) are a group of inherited metabolic disorders that are
caused for the most part by enzyme deficiencies within the lysosome resulting in …
caused for the most part by enzyme deficiencies within the lysosome resulting in …
Niemann-Pick disease type C
MT Vanier - Orphanet journal of rare diseases, 2010 - Springer
Abstract Niemann-Pick C disease (NP-C) is a neurovisceral atypical lysosomal lipid storage
disorder with an estimated minimal incidence of 1/120 000 live births. The broad clinical …
disorder with an estimated minimal incidence of 1/120 000 live births. The broad clinical …
Miglustat in Niemann-Pick disease type C patients: a review
M Pineda, M Walterfang, MC Patterson - Orphanet journal of rare diseases, 2018 - Springer
Abstract Objective Niemann-Pick disease type C (NP-C) is a rare, autosomal recessive,
neurodegenerative disease associated with a wide variety of progressive neurological …
neurodegenerative disease associated with a wide variety of progressive neurological …
Recommendations for the diagnosis and management of Niemann–Pick disease type C: an update
MC Patterson, CJ Hendriksz, M Walterfang… - Molecular genetics and …, 2012 - Elsevier
Niemann–Pick disease type C (NP-C) is a rare inherited neurovisceral disease caused by
mutations in either the NPC1 (in 95% of cases) or the NPC2 gene (in around 5% of cases) …
mutations in either the NPC1 (in 95% of cases) or the NPC2 gene (in around 5% of cases) …
Niemann‐Pick type C disease: molecular mechanisms and potential therapeutic approaches
AI Rosenbaum, FR Maxfield - Journal of neurochemistry, 2011 - Wiley Online Library
J. Neurochem.(2011) 116, 789–795. Abstract Cholesterol is an important lipid of mammalian
cells. Its unique physicochemical properties modulate membrane behavior and it serves as …
cells. Its unique physicochemical properties modulate membrane behavior and it serves as …
Niemann–Pick type C disease: cellular pathology and pharmacotherapy
S Wheeler, DJ Sillence - Journal of neurochemistry, 2020 - Wiley Online Library
Niemann–Pick type C disease (NPCD) was first described in 1914 and affects approximately
1 in 150 000 live births. It is characterized clinically by diverse symptoms affecting liver …
1 in 150 000 live births. It is characterized clinically by diverse symptoms affecting liver …
Disease and patient characteristics in NP-C patients: findings from an international disease registry
MC Patterson, E Mengel, FA Wijburg, A Muller… - Orphanet journal of rare …, 2013 - Springer
Abstract Background Niemann-Pick disease type C (NP-C) is a rare neurovisceral disease
characterized by progressive neurodegeneration and premature death. We report data …
characterized by progressive neurodegeneration and premature death. We report data …
Niemann-Pick disease type C symptomatology: an expert-based clinical description
E Mengel, HH Klünemann, CM Lourenço… - Orphanet journal of rare …, 2013 - Springer
Niemann-Pick disease type C (NP-C) is a rare, progressive, irreversible disease leading to
disabling neurological manifestations and premature death. The estimated disease …
disabling neurological manifestations and premature death. The estimated disease …
Miglustat in adult and juvenile patients with Niemann–Pick disease type C: long-term data from a clinical trial
JE Wraith, D Vecchio, E Jacklin, L Abel… - Molecular genetics and …, 2010 - Elsevier
A randomized, controlled trial of miglustat indicated that miglustat (Zavesca®) stabilized
neurological disease over 12months in adult and juvenile patients with Niemann–Pick …
neurological disease over 12months in adult and juvenile patients with Niemann–Pick …
The Niemann-Pick type diseases–A synopsis of inborn errors in sphingolipid and cholesterol metabolism
FW Pfrieger - Progress in lipid research, 2023 - Elsevier
Disturbances of lipid homeostasis in cells provoke human diseases. The elucidation of the
underlying mechanisms and the development of efficient therapies represent formidable …
underlying mechanisms and the development of efficient therapies represent formidable …